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Endotoxin caused vasoconstriction in preglomerular juxtamedullary
vessels. A.A. van Lambalgen and D. Casellas, Laborato,y for Physiology,
Vrzje Universiteit, Amsterdam, The Netherlands, and Groupe Rein et Hyper-
tension, Hôpital St. Charles, Montpelier, France. During endotoxin shock
(ES), an experimental form of septic shock, there is an early increase in
renal vascular resistance, but it is difficult to decide whether this is a direct
endotoxemic effect on the renal vasculature or is secondary to early
systemic changes. To study the former possibility we used the isolated
blood perfused juxtamedulary nephron preparation (glomerular function,
tubuloglomerular feedback intact). Kidneys were isolated from 5 male
Sprague-Dawley rats (250—350 g). After microsurgery, renal preparations
were perfused with Krebs bicarbonate Ringer buffer (KBR) containing
6% albumin, amino acids and washed erythrocytes (hematncrit: 30%) and
superfused with KBR (1% albumin; 37°C). After control measurements at
= 0 the perfusion medium was changed to one with endotoxin (E. coli
0127:B8, final concentration 10 .tgIml). Total duration of the experiments
was kept within the established period of functional stability of the
preparation (120 mm). Diameters of interlobular (ILA), mid (MAA) and
juxtaglomerular (JAA, close to vascular pole) afferent, and efferent (EFA;
when visible) arterioles were measured through videomicroscopy at a
perfusion pressure of 60 mm Hg and expressed as percentage of the value
before start of the endotoxin administration (see table).
t=0 t=30min t=60min t=l2Omin
ILA (N = 7) 100 71 9° 72 15° 69 8°
MAA (N = 7)
JAA (N = 7)
100
100
77 13°
71 16°
78 15°
74 15°
79 16°
81 j4ab
EFA(N=3) 100 100±2 97±6 97±5
N is the number of vessels; ° significantly different from value at t = 0
(P < 0.05); b significantly different from ILA (P < 0.05).
Endotoxin thus has no effect on efferent arterioles, but causes an early and
sustained constriction of the different preglomerular vessels, indicating
that the early renal vasoconstriction during ES is also due to endotoxemic
effects on pre- but not on postglomerular vessels.
Effectiveness of enalapril versus nifedipine to antagonize blood pres-
sure and renal response to endothelin (ET) in humans. H.A.H. Kaasjager,
HA. Koomans, A.J. Rabelink, Department of Nephrology and Hypertension,
University Hospital Utrecht, Utrecht, The Netherlands. Infusion of ET in
humans to obtain pathophysiological plasma levels causes mild hyperten-
sion, renal vasoconstriction, and sodium retention. We studied whether
oral use of the ACE inhibitor enalapril (20 mg b.i.d.) or the calcium
channel blocker nifedipine (60 mg o.d.) could attenuate these effects of ET
in healthy volunteers. Each subject underwent a clearance study during
which ET (2.5 ng/kg/mmn) was infused for 90 minutes. Studies were
repeated after 5 days of pretreatment with oral nifedipine or enalapril.
Clearances of PAH and inulin were used as an index of renal plasma flow
(ERPF) and glomerular filtration rate (GFR), respectively; renal blood
flow (RBF) was calculated by dividing ERPF by 1-packed cell volume, and
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renal vascular resistance by dividing mean arterial pressure by renal blood
flow.
GFR mi/mm MAP mm Hg
Baseline Infusion Baseline Infusion
ET 105±9 92±10° 93±2 99±2°
ET+CEB 113±11 111±8 93±2 95±3
ET+ACEi 118±11 108±11 87±3 89±3
Sodium excretion nol/min RVR, mm Hg mm/liter
ET 158 54 86 26° 101 7 152 20
ET + CEB 277 81 199 59 91 7 111 7°
ET + ACEi 173 37 91 19° 88 10 124 11°
Values are means aP < 0.05, compared to baseline.
Treatment with enalapril reduced blood pressure and prevented the
hypertensive response to ET. By contrast, despite renal pre-dilation,
endothelin reduced RBF strongly (from 1063 127 to 763 to 100
mI/mm), although maximal RVR was lower than during endothelin alone,
and GFR was relatively maintained. Enalapril did not alter the antinatri-
uretic effect of endothelin. Nifedipine did not affect blood pressure, but
prevented the increase caused by ET. The ET-induced fall in RBF (from
1084 101 to 888 65 mI/mm) was less than during ET infusion alone,
and RVR was lower than in both experiments, whereas GFR was
maintained. Nifedipine increased basal sodium excretion, which compen-
sated for the decrease observed during superimposed endothelin infusion.
In conclusion, both enalapril and nifedipine can counteract the hyperten-
sive effects of endnthelin, but nifedipine is more effective in antagonizing
the renal effects of endothelin.
Hemodynamic and biochemical effects of AT1-receptor antagonist SR
47436 (BMS 186295) in essential hypertension. A.H. van den Meiracker,
P.J. Admiraal, Joëlle Sissmann, A.J. Man in t Veld, and M.A.D.H. Schale-
kamp, Department of Internal Medicine I, University Hospital Dijkzigt,
Rotterdam, The Netherlands, and Sanofi Recherche, Montpellier, France.
The hemodynamic, neurohumoral and biochemical effects of the novel
AT1 receptor antagonist SR 47436 (BMS 186295) were studied in 86
untreated patients with essential hypertension on a normal sodium diet.
According to a double-blind parallel group trial, patients were randomized
to a once daily oral dose of the AT1 receptor antagonist (1, 25, 100 mg)
or placebo, after a placebo run-in period of 3 weeks. Randomization
medication was given for 1 week. Compared to placebo, 24 hour ambu-
latory blood pressure did not change with the 1 mg dose, whereas it fell
(mean and 95% CI) by 7.0 (4.2—9.8)16.1 (3.9—8.1) with the 25 mg and by
12.1 (8.1—14.1)/7.3 (5.1—8.2) mm Hg with the 100 mg dose. Heart rate did
not change on either dose. With the 25 mg dose the antihypertensive effect
was attenuated during the second half of the recording, whereas with the
100 ing dose it was maintained for 24 hours. Baseline values of renin and
the antihypertensive response to the 25 and 100 mg dose were well
correlated (r = 0.68, P < 0.01). Renin did not change with the 1 mg dose,
whereas it rose 3 to 4-fold with the 25 mg and 4 to 5-fold with the 100 mg
dose 4 to 6 hours after administration. With the 100mg dose renin was still
2-fold elevated 24 hours after dosing. The AT1 receptor antagonist-
induced changes in renin were associated with parallel increments in
angiotensin I and II, although the ratio of angiotensin Ito renin tended to
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decrease. Aldosterone, despite AT1 receptor blockade, did not change. As
compared to baseline values, plasma norepinephrine moderately in-
creased with the 100 mg, but not with the 25 mg or 1 mg dose. Creatinine
clearance, serum uric acid or its 24 hour urinary excretion did not change.
In conclusion, in essential hypertension, SR 47436 (BMS 186295) once
daily effectively lowers blood pressure. This effect is maintained for 24
hours with the 100 mg dose. Unlike the AT1 receptor antagonist losartan,
SR 47436 (BMS 186295) exerts no uricosuric effect, suggesting that this is
an effect unrelated to AT1 receptor blockade.
Renin-inhibition-induced natriuresis in essential hypertension (EH) is
determined by renal vascular tone. P. van Paassen, D. de Zeeuw, G.J.
Navis, and P.E. de Jong, University Hospital, Groningen, The Netherlands.
Enhanced renal vascular tone is hypothesized to explain the impaired
renal sodium handling in EH patients. Experimental evidence suggests a
mechanistic role for the renin-angiotensin system (RAS). We tested
whether acute and/or chronic blockade of the RAS by the specific
renin-inhibitor Remikiren (Rem) would induce a more pronounced
natriuresis in EH patients with a higher initial renal vascular tone. We
therefore measured mean arterial pressure (MAP), renal hemodynamics
(GFR, ERPF, FF, RVR) and sodium excretion after a single oral dose
(600 mg, N = 17, placebo-controlled, random cross-over) and after 8 days
treatment (600 mg o.i.d.; metabolic ward; N = 8). All patients were on a
diet containing 50 mmol Na and 100 mmol K. Single dose Rem induced a
fall in MAP from 108.6 1.5 to 99.4 1.7 mm Hg (8.5%, P < 0.05).
Filtration fraction (FF) fell from 0.253 (0.211—0.321) to 0.231 (0.182—
0.304) (8.7%, P < 0.05) and renal vascular resistance (RVR, mm Hg X
min/mI/1.73 m2) fell from 0.258 (0.188—0.335) to 0.222 (0.149—0.315)
(14.6%, P < 0.05). A cumulated sodium loss of +5.1 mmol/hr (8.8—24.6)
occurred. After 8 days treatment MAP fell from 108 2 to 96 2 mm Hg
(11.5%, P < 0.05). FF fell from 0.230 (0.208—0.249) to 0.207 (0.189—
0.239) (10%, P < 0.05) and RVR fell from 0.240 (0.148—0.288) to 0.204
(0.140—0.257) (15%, P < 0.05). During Rem, a cumulated sodium loss of
72 30 mmol (—46—+ 187) occurred. The natriuretic response varied
considerably within both groups. Interestingly, Rem induced a greater
cumulative sodium loss in patients with a higher initial FF and RVR, both
after a single dose: r = 0.72, P < 0.01; r = 0.52, P < 0.05, respectively, and
after 8 days treatment: r = 0.75, P < 0.05 and r = 0.73, P < 0.05,
respectively. In both groups cumulative sodium excretion was not related
to the fall in MAP. In conclusion, a higher renal vascular tone in a subset
of EH appears to play a role in the impaired sodium handling in these
patients. This could be due to functional, RAS mediated changes in the
renal vasculature, since both acute and chronic treatment with a specific
renin-inhibitor predominantly enhanced natriuresis in these patients.
The standard peritoneal permeability analysis a better measure of
peritoneal function than the peritoneal equilibration test (PET). MM.
Pannekeet, D.G. Struijlc L. Arisz, and R. T Krediet, Academic Medical
Cente, Amsterdam, The Netherlands. The PET test is widely used to assess
peritoneal transport in CAPD patients. After a 4 hour dwell of glucose
2.27% dialysate the dialysate/plasma ratio of creatinine (D/P), the dialy-
sate/initial dialysate ratio of glucose (DID0) and net ultrafiltration (NUF),
that is the drained minus the instilled volume, are calculated. Based on the
values of solute transport patients are divided into low, low-average,
high-average and high transporters. Recommendations are given for the
quantity and mode of peritoneal dialysis according to the transport status.
The SPA differs from the PET because glucose 1.36% dialysate is used to
which dextran 70 (1 g/liter) is added to calculate fluid kinetics. The mass
transfer area coefficient of creatinine (MTAC) is calculated using first
order kinetics, the amount of glucose absorbed is expressed as a percent-
age of the instilled dose (GA), and the change in intraperitoneal volume
during the dwell (1PV) is determined from the dilution of dextran after
correction for incomplete recovery. The parameters obtained in the PET
can be used to calculate the MTAC and GA. One hundred thirty-eight
SPA's were done in 86 clinically stable CAPD patients, and the duration
of CAPD ranged from 0.33 to 13.9 years (median 3.1). Median (ranges) of
the transport parameters were: MTAC:10.4 mI/mm (5.7 to 19.3); GA:61%
(35—87); zIPV:9.5 ml (—761—310). From the same tests the parameters
used in the PET were calculated: D/P:0.76 (0.53—1.14); D/D0:0.37 (0.13—
0.56); NUF: —75 ml (—675—450). Strong correlations existed between D/P
and MTAC (r = 0.85, P < 10-i), D/D0 and GA (r = —0.91, P < 10-s) and
NUF and MPV (r = 0.68, P < 10). However, the agreement between
two methods should be assessed by examining the relation between the
difference between the methods and their mean in all separate tests, for
example (D/P — MTAC) versus 0.5 (DIP + MTAC). For UF a random
distribution of the difference between the NUF and zIPV was present. A
correlation was found between (D/P — MTAC) and 0.5 (DIP + MTAC):
r =
—0.83, P < io. D/P overestimated MTAC >10% mainly in the low
range (N = 31), whereas in the high range values were underestimated
>10% (N = 41). This occurs because D/P is dependent on both diffusive
and convective transport, whereas MTAC is only determined by diffusion.
The correlation coefficient for (DID0- GA) versus 0.5 (D/D) + GA) was
0,67 (P < 10): 61 GA were underestimated by D/D() (high range) and 54
were overestimated (low range). We divided the patients similar to the
PET: 60 of 138 patients were misplaced (37% in the low D/P group, 61%
of the low average, 51% of the high average, and 4% of the high
transporters). For D/D0 this was 31 of 138 patients 29%, 25%, 15% and
29%. It can be concluded that the SPA is a better measure of peritoneal
transport than the PET, because PET underestimates in the high range
and overestimates in the low range. PET can be improved by using the
results of the dialysate and plasma determinations to calculate MTAC and
GA.
Nitrate in stable CAPD patients and during peritonitis. CE. Douma,
D.R. de Waart, D. Zeme4 AL. T. Imholz, D.G. Stnajk and R. T. Krediet,
Academic Medical Center, Amsterdam, The Netherlands. During CAPD the
peritoneal vessels are dilated. Nitric oxide (NO) is an endothelium derived
relaxing factor and causes vasodilation in many organs. In 6 stable CAPD
patients standard peritoneal analyses were performed. Nitrate, a stable
metabolitc of NO, was measured in plasma and dialysate. The mass
transfer area coefficient (MTAC) of nitrate was 12.04 0.95 mI/mm
(mean sEM). The MTAC of creatinine was in the same range (11.11
0.83 ml/min), although the molecular weight of nitrate is lower (62 vs. 113
kD). The correlation between the MTAC nitrate and the MTAC creati-
nine pointed to diffusion from the circulation and not to local production
of NO (r = 0.71; P 0.11). In the acute phase of peritonitis the peritoneal
permeability is increased, caused by extensive vasodilation. In this situa-
tion relations have been found between permeability characteristics and
various cytokines and prostaglandins, especially the vasodilating. NO, a
common pathway for vasodilation, is important in septic shock. Therefore,
we investigated the potential role of NO during peritonitis. Eleven
peritonitis episodes in 8 CAPD patients were studied both in the acute
phase and after recovery. Night dwells were used and nitrate was
measured both in plasma and dialysate. In another patient all effluents
were collected from the first to fourth day of peritonitis. The dialysate/
plasma (DIP) ratio of nitrate in the acute phase was higher (1.51 0.15)
than after recovery (1.15 0.06; P < 0.05). No relation was found
between DIP ratio of nitrate and D/P ratio of TNFa. The DIP ratio of
nitrate in the patient followed during consecutive dwells was highest in the
first effluent (1.51). In the second dwell the DIP ratio was 1.23 and in the
third dwell 1.05. Thereafter it remained at the same level (1.02 0.008, 11
dwells). No difference was found in plasma nitrate in the acute phase (94.0
smol/liter) and the following days (96.6 4.3). The DIP ratio of
creatinine in the first effluent was 1.00 and was almost similar the other
days (0.94 0.014). Conclusion: Dialysate nitrate levels in stable CAPD
patients are likely to be determined by diffusion from the circulation. The
relatively low MTAC values may be caused by the presence of a water
shell. D/P ratios exceeding 1.0 during the acute phase of peritonitis are
probably the result of local NO production. This may contribute to the
marked vasodilation during peritonitis, leading to increased solute transport.
Direct podocyte damage leads to in vivo single nephron albuminuna. W.
Laurens, C. Battaglia, C. Foglieni, B. Malanchini, B. Van Damme, Y.
Vanrenterghem, G. Remuzzi, and A. Remuz4 Laboratori Mario Negri,
Institute for Pharmacological Research, Beigamo, Italy, and Departments of
Nephrology and Pathology, University Hospital, Catholic University Leuven,
Leuven, Belgium. Recently, we demonstrated that microinjection of a
saponin (S) solution in Bowman's space of superficial glomeruli of female
Munich-Wistar-FrOmter rats induces direct damage to the podocytes
without ultrastructural lesions to the endothelial cells or to the basement
membrane. In this model we now tested the hypothesis that detachment of
podocytes leads to albuminuria in vivo. After the microinjection of the
glomeruli with the S solution, the animals were installed under a fluores-
cence microscope, a purified fluorescinated rat albumin solution was
intravenously injected, and the passage of the fluorescent albumin was
followed through the microscope. Of the 47 glonieruli injected with the S
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solution (in 6 animals), 46 became fluorescent within seconds with the
fluorescence progressing from Bowman's space into the proximal tubule
and then in the rest of the tubule. In superficial non-injected and
control-injected glomeruli only weak fluorescence could be detected in the
flocculus and in the peritubular capillaries. Tubuli injected with the S
solution remained undistinguishable from non-injected tubuli. Electron
microscopic study of the S injected glomeruli confirmed the selective
removal of podocytes. Conclusions: Selective removal of podocytes at the
single nephron level leads to albuminuria in vivo and therefore podocytes
play a crucial role in regulating the permeability of the glomcrular
capillary wall.
Enhanced glomerular permeability and minimal change disease-like
alterations of the rat kidney induced by a vasoactive human plasma
factor. P.K. Cheung, F. W.D. Dijkhuis, P.A. Kiok, and W. W. Bakker,
Department of Pathology, University of Groningen, Groningen, The Nether-
lands. The pathogenesis of proteinuria in minimal change disease (MCD)
is not understood. It has been suggested that circulating factors, toxic for
the glomerular filtration barrier, are involved. Previously we have detected
a 100 kD vasoactive factor in normal human plasma (partly purified),
denoted as 1 OOkF. Incubation of human or rat kidney tissue with lOOkF
resulted in histochemical alterations in kidney tissue in vitro, similar to
those seen in biopsies from subjects with MCD [decreased glomerular
sialoglycoproteins (SGP) as well as decreased glomerular ADPase}. The
question was raised whether lOOkF is also able to induce increased
glomerular permeability for plasma proteins. Therefore, we conducted
alternate perfusion studies in the rat kidney er vivo according to standard
procedures. Perfusion with either lOOkF (1.5 mg/mI; N = 7) or control
factor, that is heat-inactivated lOOkF (1.5 mg/ml; N = 6) was followed by
perfusion with a permeability marker (diluted normal rat plasma). Urine
of perfused kidneys was collected by ureter cannulation. After perfusion
kidney specimens were processed for histochemistry, and urinary protein
was analyzed using spectrophotometry. Glomerular stainability was quan-
tified by computerized image analysis (50 glomeruli per animal were
evaluated) and expressed as arbitrary units. The results show a significant
decrease of glomerular ADPase activity (28.7 10.7 vs. control: 79.5
15.0; P < 0.01) as well as a decrease of GSP stainability (57.3 25.5 vs.
control: 98.4 12.0; P 0.05). In addition, in urine of lOOkF-treated
animals increased amounts of plasma proteins can be detected (150.0
49.0 jsg/min), in contrast to animals perfused with the control factor (32.9
8.3 jtglmin; P s 0.01). Moreover, preliminary data show significantly
decreased IgG/albumin ratios in the urine from lOOkF perfused rats,
suggesting selectivity of protein excretion. It is concluded that lOOkF is
able to enhance the glomerular permeability of the rat kidney for plasma
proteins. Since previous observations also suggest activation of lOOkF
exclusively in plasma from subjects with MCD in relapse, we feel that this
factor may be important in the pathogenesis of proteinuria in this
disorder.
Urinary excretion of 2-microglobulin predicts renal outcome in pa-
tients with idiopathic membranous nephropathy. L.J.M. Reichert, RAP.
Koene, and J.F.M. Wetzels, Department of Medicine, Division of Nephrology,
University Hospital Nzjmegen, Nijmegen, The Netherlands. In the majority of
patients with idiopathic membranous nephropathy the disease follows a
benign course, with only a quarter of patients developing renal insuffi-
ciency. Immunosuppressive treatment of all patients would expose the
majority of patients unnecessarily to potentially toxic drugs. At the
moment it is not possible to identify in an early stage those patients with
the highest risk for developing renal insufficiency. We have evaluated the
possible role of urinary ,!32-microglobulin excretion in identifying such
patients. Thirty patients (24 males, 6 females: median age 44.5 years, range
24—61 years) were studied 2 months (range 0—140 months) after renal
biopsy. At this time point urine samples were collected for measurement
of 32-microglobulin. All patients had an ECC > 80 mI/mm and were
nephrotic, with a median proteinuria of 8.0 g per day (range 5.1—28.5 g per
day) and a median serum albumin of 22.8 g per liter (range 7.4—32 g per
liter). At the end of follow-up (median 48 months after measurement of
urinary 132-microglobulin, range 12—132 months) renal function had dete-
riorated in 13 patients. Renal function deteriorated in 11 of the 14 patients
with a 132-microglobulin excretion > 500 nglmin and in 2 of the 16 patients
with a 32-microglobulmn excretion 500 nglmin (P < 0.001). Using
multivariance analysis for the dichotomized factors (sex, age, hyperten-
sion, proteinuria, serum albumin and urinary 32-microglobulin excretion)
a significantly worse prognosis was independently associated with a low
serum albumin (<15 g/liter, P < 0.05) and a urinary 2-microglobulin
excretion >500 ng/min (P < 0.01). These data suggest that urinary
P2-microglobulin excretion could be valuable in identifying patients with
membranous nephropathy at risk for the development of renal insuffi-
ciency.
Normalization of renal hemodynamics by intravenous dopa in normo-
tensive ADPKD patients. J.N.M. Barendregt, K W. Florzjn, P.C. Chang,
Department of Nephrology, University Hospital Leiden, Leiden, The Nether-
lands. To study their intrarenal synthesis and effects of dopamine (DA),
we investigated eight normotensive ADPKD patients with (near) normal
renal function and seven healthy controls (CON) at 3 levels of dietary
sodium intake: 150 (NoSo), 50 (LoSo) and 450 mmol Na (HiSo). Renal
vascular and excretory responses were studied during intravenous DOPA
(DOPA iv., 7 jsg - kg1 min') at HiSo, to stimulate intrarenal DA
synthesis, and during intravenous enalaprilate (ACEI, 42 sg kg1),
followed by angiotensin II (AT iv., 12 ng kg' min') administration at
LoSo. Glomerular filtration rate (GFR) and effective renal plasma flow
(ERPF) were measured by continuous infusion of inulin and PAH.
Cumulative sodium balances were equal. Urinary excretions of DOPA and
DA were higher (P < 0.01) in ADPKD than in CON at all levels of sodium
intake. ERPF was lower, and filtration fraction (FF) and blood pres-
sure higher in ADPKD (all P < 0.05). Plasma aldosterone was higher in
ADPK.D at HiSo (P < 0.05). DOPA iv, induced similar natriuresis in both
groups and normalized ERPF and FF (P < 0,05) in ADPKD. ACEI
increased ERPF and decreased FF in ADPKD, but these remained higher
than in CON. No clear differences in responses to ACEI and AT iv. were
found. In conclusion, in ADPKD natriuresis appears to be well-regulated,
and intrarenal DA synthesis may be stimulated. Responses to DOPA iv.
suggest a deficient intrarenal dopaminergic vasodilating tone in ADPKD.
Biphasic granulocytopenia after administration of the first dose of
OKT3. F.J. Bemelman, S. Buysmann, S.L. Yong F.N.J. van Diepen, S.
Surachno, f.M. Wilmink, P. Th.A. Schellekens, and R.J.M. ten BeiTe, Aca-
demic Medical Center, University of Amsterdam, Renal Transplant Unit and
Clinical Immunology Unit, Amsterdam, The Netherlands. In renal allograft
recipients, the effects of administration of OKT3 (N = 8), a second
IgG2a— (N = 11), and its isotype switch variant IgA anti-CD3 mAb (N =
9) on granulocyte kinetics were compared during 5 hours after the first
administration of the mAb. In addition, in vivo and in vitro studies were
performed on alterations in expression of CD11b and L-selectin induced
by these mAb. Within 15 minutes after administration, OKT3 and IgG2a
anti-CD3 mAb induced a significant decrease in circulating granulocytes
(to 35 8% and 81 4% of pretreatment value, respectively) whereas
IgA anti-CD3 mAb did not (P < 0.034). Apparently, the initial decrease
in circulating granulocytes depends on the heavy chain of the administered
anti-CD3 mAb resulting in immunocytoadherence and sequestration of
granulocytes in the lungs. Increased adherence to pulmonary endothelium
by altered expression of CD11b and L-selectin seems to plays a minor role.
The second phase in granulocyte kinetics, occurring 60 minutes after
administration of each mAb in vivo, correlated with a significant increase
of expression of CD11b (to 178 36% and 332 52% of pretreatment
value in viva, respectively in vitro) and down-regulation of L-selectin in
vitro (to 46 15%) but not in vivo. The difference between kinetics of
adhesion molecules in vivo and in vitro could be explained by selective
disappearance from the circulation of granulocytes expressing high levels
of CD11b and low levels of L-selectin. Alterations in expression of
adhesion molecules were related to the presence of tumor necrosis factor
(known to be released in vivo after the first dose of OKT3) both in vivo and
in vitro. Anti-CD3 mAb-induced changes in expression of adhesion
molecules in whole blood could be completely antagonized by co-incuba-
tion with an anti-TNF mAb. Granulocyte kinetics from 30 minutes after
administration of each anti-CD3 mAb resemble neutrophil kinetics in-
duced by TNF.
Dialyzer elution: A reproducible technique for biocompatibility studies.
iC. Bos, MP.C. Grooteman, M.J. Nubé, A.J. van Houte, M. Schoorl, and
J.A. van Geelen, Departments of Nephrology and Immunohaematology,
Medical CenterAlkmaar, Alkmaar, The Netherlands. In hemodialysis (HD)
the main bioeompatibility (BC) indices used are peripheral blood derived.
However, bioincompatibility originates in the dialyzer itself, and therefore
leukocytes adherent to the membrane might be a representation of
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bioincompatibility processes. We developed a dialyzer elution technique
in order to enable the study on adherent cells as an index of BC. The aim
of the study was twofold: firstly to obtain exclusively adherent cells (AC)
instead of passenger cells (PC) residing in the dialyzer, and secondly to
collect the eluate in appropriate condition for lightmicroscopic (LM), and
flow cytometric (FC) analysis. Two matched chronic HD patients were
treated with bicarbonate HD for 3 hours on a first-use polysulphon (F6)
membrane with heparin anticoagulation. At the end the blood was
returned to the patient with NaC1 0.9%. Then, recirculation was per-
formed for 20 minutes (flow 200 mI/mm, dialysate ports clamped) with: (a)
PBS after rinsing with 250 ml PBS; (b) PBS/EDTA 3 mi after rinsing with
250 ml PBS; (c) PBS without rinsing; and (d) PBS/EDTA 3 mM without
rinsing (total number of experiments was 27). Immediate assessment of
peripheral blood (PB) after 3 hours of HD and of the rinsing, eluate, and
afterwash samples showed that rinsing reduced the WBC count consider-
ably while the DIFF in the rinsing and cluate samples were similar.
Recirculation with PBS/EDTA 3 mrvt without rinsing showed the highest
WBC count (34.5 4.1 x 106) of all experiments while the DIFF
contrasted considerably with PB (neutrophils 85.3 2.6% versus 66.8
1.6% in PB, and lymphocytes 6.0 2.6% versus 22.1 1.2%), strongly
suggesting elution of AC instead of PC. Trypsin afterwash yielded another
40% of WBC after PBS and another 28% after PBS/EDTA recirculation
while the DIFF was similar to that in the eluate. WBC viability of all
samples was >95% and LM and FC analysis could be performed in the
usual way. As experiment d yielded the highest WBC count, we conclude
that elution with PBS/EDTA 3 mu without rinsing, for 20 minutes, im-
mediately after HD appeared to be the best reproducible clution technique.
Renal artery stenosis caused by fibromuscular dysplasia: Results of
surgery and balloon angioplasty. B. C. van Jaarsveld, F.H.M. Derkx and
M.A.D.H. Schalekamp, University Hospital Rotterdam/Dijkzigt, Rotterdam,
The Netherlands. Fibromuscular dysplasia (FMD) causes about 10% of
renal artery stenoses. The results of surgery and percutaneous translumi-
nal renal angioplasty (PTRA) in atherosclerotic stenosis are disappoint-
ing. Results in FMD are believed to be better. On the other hand diagnosis
may be more difficult in FMD, because of the peripheral localization of
stenosis (segmental arteries). We describe here our experience with the 43
FMD patients referred to our department during the last 15 years. All
patients were referred for diagnostic work-up because of hypertension
which was difficult to treat with medication. Apart from the principal
occurrence in women (91%), a remarkable finding was the preponderance
of right-sided localization; in 22 of 26 patients with unilateral FMD the
right renal artery was affected. Extrarenal fibromuscular dysplasia was
present in 7 patients in lienal, coeliac, mesenteric or iliac arteries. The
disease was diagnosed at middle-age (39.7 11.6 years, mean so), after
a short duration of known hypertension (median 2.5 years). Untreated
blood pressure, which was known in 25 patients, was 187 38/115 19
mm Hg. An abdominal bruit was present in 19 patients. There were no
other clinical clues for FMD. Renal scintigraphy was positive in 23/30
patients (77%), and renal venous renin sampling in 29/41 (71%). These
results are comparable with our experience in patients with atherosclerotic
renal artery disease. PTRA was performed in 27 patients. It was intro-
duced in 1980 and was the primary treatment from 1984 onward. In 3
patients PTRA was technically not successful. Of these, 2 underwent
nephrectomy after an attempt of surgical revascularization, and in 1
hypertension was eventually regulated with medication. Surgical recon-
struction was the primary therapy in 4 patients, in I followed by nephrec-
tomy. In 1 patient nephrectomy was the primary treatment. In spite of
their referral because of drug-resistant hypertension, on reevaluation 11
patients appeared to respond well on antihypertensive medication. Of the
8 patients treated surgically (Nx 5), hypertension was cured in 6 and
improved in 2, according to the criteria of the Working Group on
Renovascular Hypertension (1987). Median follow-up period was 8 years
(range 2—12). Of the 24 PTRA patients, 11 were cured, 8 improved and in
5 PTRA failed to lower blood pressure. Median follow-up period was 2
years (range 0.3—10). In all patients renal function was normal and did not
deteriorate after treatment. We conclude that FMD is not restricted to
young women. Most commonly the right kidney is affected. Sensitivity of
renal scintigraphy and renal vein renin measurements in FMD is not
inferior as compared to atherosclerotic stenosis. Results of PTRA are
better than those reported in atherosclerotic disease.
Renal failure in mitochondrial myopathy, encephalopathy, lactic ad-
dosis, and stroke-like episodes (MELAS). RH. Kauffmann, and fL. van
Doom, Leyenhurg Hospital, The Hague and Diaconessenhuis, Voorbui The
Netherlands. MELAS constitutes a syndrome of encephalopathy with
stroke-like episodes, progressive muscle weakness and occasionally car-
diomyopathy. Short stature and mental retardation may be present. The
underlying defect of this condition (which usually has its onset before 15
years of age and may be inherited maternally) is a mitochondrial (Mt)
DNA mutation of muscle at nucleotide position 3,243. It is characterized
by high lactate levels, ragged-red muscle fibers and succinate dehydroge-
nase (SDH) staining of blood vessel walls. This report describes the first
case of renal insufficiency in MELAS. A 21 year-old male presented with
headache with vomiting, disturbances of speech, vision and conscious-
ness and convulsions. He had a slow motor and mental development in
childhood. There was no neurological disease among his relatives. Physical
findings were: height 150 cm, weight 38 kg, blood pressure 120/90 mm Hg,
pulse 116, an enlarged heart with an apical S3, central aphasia, right-sided
hemianopsia and transient hemiplegia and normal muscle strength. Lab-
oratory examination showed: creatinine 160 mol/liter, creatinine clear-
ance 26 mI/mm, lactate 2.9 mmol/liter, fructoaldolase 1.3 and creatine
kinase 40 pjliter, protein 59 g/liter and albumin 32 g/liter. The urine
contained no cells. The 24 hour urinary protein excretion was 3.4 g.
Electro- and echocardiographic examination showed hypertrophic non-
obstructive cardiomyopathy. The cranial CT scan disclosed a large area of
low density in the left parietal region and basal ganglia calcification. The
spinal fluid examination and an electromyogram were normal. A biopsy of
the quadriceps muscle showed slight atrophy of type 1 fibers and no
ragged-red fibers. Sixty percent of mt DNA was mutated at position 3,243.
A renal biopsy showed varying degrees of ischemic glomerular damage,
tubular atrophy and interstitial fibrosis. The small arteries were narrowed
by concentric media thickening. On SDH staining accumulation of densely
stained granules was found in arterial walls. This case shows that in
MELAS ischemic damage due to abnormal metabolism of smooth muscle
cells of arteries may involve the kidneys in the same way as the brain.
Carbamylated hemoglobin: An urea-derived index of uremia. W.D.
Kloppenhurg CA. Stegeman, B. G. Woithers, T Tepper, P.E. de Jong, and
R.M. Huisman, Groningen Institute for Drug Studies (GIDS), Departments
of Medicine and Clinical Chemistry, University Hospital, Groningen, The
Netherlands. In hemodialysis patients carbamylated hemoglobin (CarHb)
has been suggested to be a long-term time-integrated urea-derived index
of uremia, since CarHb values correlate with time-averaged urea concen-
trations (TACu). Urea spontaneously dissociates in ammonia and isocya-
nate. CarHb is the end-product from the nonenzymatic post-translational
modification of hemoglobin (Hb) by isocyanic acid. We questioned
whether CarHb values can be affected by other factors than urea concen-
tration, such as total plasma carbon dioxide (C02) content, Hb concen-
tration and the rate of erythropoiesis, and whether CarHb can be used to
estimate TACu. We therefore measured midweek predialysis concentra-
tions of CarHb, C02, Hb, and the number of reticulocytes (Retic) and
monitored TACu (3-sample method) in 23 stable, thrice-weekly hemodia-
lyzed patients aged 55 16 (mean SD) years. The patients were
well-dialyzed according to their Kt/V of 1.04 (range 0.82—1.59). Results are
listed in the table.
CarHb'
jrgCV/gHb
TACu
mmol/liter
CO2
mmol/liter
Hb
g/liter
Retic
0/00
124 37 17.2 3.4 21.9 3.0 108 13 17 7
(71—195) (10.2—23.4) (15.7—25.7) (84—136) (8—33)
Mean SD (range); normal reference values: 20—60 .rg carbamyl
valine (CV)/gHb
Carl-lb values were elevated in all patients and correlated positively with
TACu (r, = +0.65, P < 0.005, Spearman) and inversely with CO2 (r =
—0.48, P < 0.05). No correlation was found with Hb or Retic. Using
partial correlation analysis of CarHb and CO2 controlling for TACu,
CarHb still correlated inversely with CO2 (r =
—0.46, P < 0.05),
suggesting that CO2 is an independent covariate of CarHb. To evaluate
whether TACu can be estimated from CarHb and the other variables,
stepwise multiple linear regression analysis of TACu on CarHb, C02, Hb
and Retic was used. The best model (r2 = 0.44) included only Carl-lb
[b(SEb) = +0.065 (0.016), p = 0.00051. This suggests that 56% of the
variance of TACu is attributed to other factors than CarHb. Inclusion of
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the effect of total CO2 content in the estimation of TACu did not increase
the accuracy of the estimate, despite the correlation between CO2 and
CarHb. In conclusion, in stable hemodialysis patients CarHb values
correlate positively with TACu and inversely with total CO2 content. It
remains to be elucidated whether this correlation is actually an effect of
the acid-base Status on CarHb levels or is due to a third unmeasured
factor. Estimation of TACu by a single measurement of CarHb is
hampered, since only a small part of the variation in TACu is explained by
the variation in CarHh levels.
Actin is directly associated to aminopeptidase A (APA) in brush border
membranes from mouse kidney. S. Mentzel, E. de Leeuw, J.P.H.F. van Son,
R.A.P. Koene, and KIM Assmann, University Hospital Nijmegen, Nijme-
gen, The Netherlands. APA is a hydrolase present on glomerular visceral
epithelial cells and brush borders (BB) of proximal tubular epithelial cells.
Injection of mAb (ASD-4) against this enzyme in mice induced a
glomerulonephritis, characterized by an acute albuminuria. In the acute
phase the enzyme APA is redistributed from the BB to the basolateral side
of the proximal tubular cells. APA was purified from solubilized BB with
ASD-4 by immunoaffinity. In SDS-PAGE under reducing conditions an
additional 43 kD band was seen that co-precipitated with the 140 kD APA
band. This 43 kD band was not seen when SDS-PAGE was run under
non-reducing conditions. The 43 kD band was excised from the gel,
trypsinized, and the peptides separated by HPLC. Three tryptic peptides
were subjected to internal amino acid sequencing. A Pearson and Lipman
database search of these sequences revealed 100% homology of all three
peptides with actin. Western blotting of affinity purified APA showed
positive staining of the APA band when incubated with ASD-4. Incubation
of this Western blot with an antibody against a and -y actin stained the 43
kD band, and not the APA band. These Western blotting data and the fact
that only the 13 and y isoforms exist in proximal tubular cells, suggests that
it is the y isoform of actin that is associated to APA. We conclude that the
co-purification of APA and actin from the BB of proximal tubular cells is
due to the tight binding between them through disulfide bridges. This
indicates a direct association of actin to APA in vivo without the
intermediary binding of other proteins. A likely candidate for disulfide
bridge formation is a cysteine residue in the short cytoplasmic tail of APA.
The direct binding of aetin to APA might suggest a role in the observed
tubular redistribution of APA.
Determinants of renal hemodynamics in terminal respiratory failure.
H. Potthojf G.J. Navis, H. Buter, P.1 de Kam, and P.E. de Jong, Department
of Nephrolo, University Hospital Groningen, Groningen, The Netherlands.
In respiratory failure GFR is often impaired, with a disproportionally low
ERPF. Its mechanism is incompletely understood and studied mostly in
patients with chronic obstructive pulmonary disease (COPD). Proposed
mechanisms are hypoxemia, hypereapnia, polycythemia and low cardiac
output. We analyzed data on renal (GFR and ERPF; clearances of
'251-iothalamate and '311-Hippuran) and systemic hemodynamics, arterial
blood gases and hematocrit in 84 patients referred for lung transplanta-
tion. Diagnoses were: primary pulmonary hypertension (PPH; N = 11),
cystic fibrosis (N = 22) and miscellaneous, including COPD (N 51). All
patients were free of signs and symptoms of Overt renal disease. Main
parameters and their Pearson correlation coefficients were:
CI liter/rn/mm 3.1 (1—5.6)
pCO, kPa 5.6 (3.4—10)
P°2 kPa 7 (3.1—12.3)
Hct % 43 (29—52)
______________________________
P < 0.0001.
In contrast with other studies renal function impairment was most
pronounced in patients with low pCO2. Multiple regression analysis
revealed this was due to preponderance of a low cardiac index (CI) in
hypocapnic patients, associated with pulmonary hypertension. Indepen-
dent determinants were Cl and pulmonary vascular resistance for ERPF,
and Cl and age for GFR. Results of the analysis were essentially similar
after excluding cystic fibrosis patients. Thus, in patients with terminal
respiratory failure, cardiac performance is the main physiological param-
eter determining renal function.
Angiotensin II and the renal nerve in the regulation of renal hemody-
namics during severe constant reduction of renal perfusion pressure.
G.H. Verseput, B. Braam, A.P. Provoost, and HA. Koomans, Department of
Nephroloy, University Hospital Utrecht and Department of Paediatric
Surgery, Erasmus University Rotterdam, The Netherlands. Although the role
of angiotensin II (Ang II) and renal nerve activity (RNA) in the control of
renal hemodynamics has been studied extensively, their role in the acute
adaptation to unilateral renal artery stenosis has received less attention. It
is likely that the decrease in renal perfusion pressure (RPP) in this
situation recovers at least partially through an Ang Il-mediated increase in
mean arterial pressure (MAP). The ipsilateral nerve probably contributes
to this effect since ipsilateral renal denervation (dnx) is reported to
ameliorate hypertension in Goldblatt rats. If this is true the direct negative
effects of Ang II and RNA on renal function may well be obscured.
Therefore, left kidney glomerular filtration rate (LGFR) was studied in
pentobarbital-anesthetized male Sprague Dawley rats during acute reduc-
tion of mean left RPP (LRPP) to a level maintained constant at 75 mm Hg
by adjusting an aortic sling between the renal arteries. LRPP and MAP
were monitored in the femoral and carotid artery, respectively. Control
rats (Con, N = 6), rats administered a 10 mg/kg bolus of the AT1-
antagonist losartan (Los, N 6), and rats subjected to acute left dnx
(Ldnx, N = 6) underwent a clearance protocol of 4 periods of 30 minutes.
A baseline period (Base) was followed by 2 periods (Sten 1, Sten 2) with
reduction of LRPP to 75 mm Hg and a recovery period (Rec). Infusion
rate during Sten was reduced to 50% to prevent volume expansion.
Group Parameter Base
Con
Los
Ldnx
- -
LGFR
MAP
LGFR
MAP
LGFR
MAP
1.41 0.07
126±2
1.50 0.12
110±6
1.42 0.11
116±5
Group Sten I Sten 2 Rec
Con
Los
Ldnx
No urine142 3
0.48 0.17"
116±6"
0.40 0.07"
128±3"
No urine
145 5"
0.47 0.15"
114±6
0.55 0.07"
132±3"
1.26 0.04
118 4
1.41 0.09
107±5
1.63 0.14
116±4
Mean survi; LGFR in mi/mm, MAP in mm Hg; "P < .05 vs. Base
(2-way ANOVA)
Apparently, in the presence of active Ang II and RNA, the decrease of
LRPP to 75 mm Hg leads to cessation of urine production. If either Ang
11 or RNA are inactivated, renal function is better preserved at -30—40%
of baseline despite similarly low LRPP. These data indicate that the
beneficial effect of Ang II and ipsilateral RNA on renal function during
renal artery stenosis depends upon restoration of RPP by systemic
hypertension, whereas their direct effect on renal function is detrimental.
Renal hippurate clearance and renal blood flow. C.A. Visscher, R.M.
Huisman, G.J. Navis, P.E. defong, and D. de Zeeuw, Department of Internal
Medicine, University Hospital, Groningen, The Netherlands. Renal hippu-
rate clearance is supposed to reflect renal blood flow (RBF), when
corrected for renal hippurate extraction (E5,) and hematocrit (Het). We
compared RBF measured by renal blood flow probes (RBFPrObC) and renal
1311-hippurate clearance (RBFhI1,) corrected for E5 (renal vein sampling)
and Hct in conscious chronically instrumented dogs in two ways: (A)
actual values in normal (non-RVH; N = 5) and renovaseular hypertensive
dogs (RVH; N = 9); and (B) placebo-controlled changes induced by
ACE-inhibition (ACEi), angiotensin-Il (Ang II), nitroprusside (NP),
indomethacin (IN), dopamine (DA), and norepinephrine (NE) in non-
RVH (N = 6). (A) RBFhP exceeded RBFPrOSC in both non-RVH (591
GFR ml/min ERPF mI/mm
Median/range
103 (30—191) 374 (101—762)
0.66a
0.62"
0.07
—0.08
0.70"
0.63"
0.06
—0.06
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45 vs. 410 31 mI/mm) and RVH (620 47 vs. 330 48 mI/mm). Even
when renal venous blood is submitted to the earliest possible centrifuga-
tion (2 mm), Eh was underestimated by 12—37%. Extrapolation of this
value back to 0 minutes, however, resulted in a comparable RBFhI (395
and 366 mi/mm) and RBFPrOF,C (385 and 3,1 mI/mm). (B) Although
drug-induced changes in RBFprObC (table) exceeded changes in RBFhI
(+ 11 5 vs. +6 4%, P < 0.05), changes in RBFhIP correlated well wit
changes in RBFpr,b (r = 0.70, P < 0.01). Moreover, even when changes
in EhIP are omitted, changes in renal hippurate clearance (ChiP) well
reflected changes in RBFprohe (r = 0.57, P < 0.05).
RBFprObC RBFhP C51 Eh
ACEi +44 12 +35 9 +26 5 —5 2a
Ang II —26 Y' —24 2 —19 1 +5 2
NP +13±6 +11±5 +14±4a —1±1
IN —7±3 +1±2
DA +33 5 +28 6 +16 + 4 7 p
NE +i8±3 +6+4 +2±6 —2±3
Mean SuM (% change of baseline). P < 0.05 vs. placebo.
In conclusion, these data indicate that the actual value of RBF when
established by RBFhiP is substantially overestimated, due to underestima-
tion of Eh. Drug-induced changes in RBF, however, are reasonably
reflected by changes in RBF5, even when changes in E5 are neglected.
Preserved endothelium-dependent forearm vasodilation in renal trans-
plant patients with cyclosporine-induced hypertension. MA. van den
Dorpel, A.H. van den Meiracker, T. W. Lameris, A.J. Man in 't Veld, R. Zietse,
M.A.D.H. Schalekamp, and W. Weimar, Department of Internal Medicine I,
University Hospital Dzjkzigt, Rotterdam, The Netherlands. The clinical use of
cyclosporine A (CsA) is often accompanied by hypertension. Both in Vitro
and animal studies have provided evidence that CsA impairs endothelium-
dependent vasodilation, which may lead to an increase in vascular
resistance and arterial pressure. To determine whether CsA also interferes
with in vivo endothelium-dependent vascular relaxation in human subjects,
the vasodilator response of the forearm vascular bed to acetyicholine
(endothelium-dependent) and sodiumnitroprusside (endothelium-inde-
pendent) was studied in renal transplant patients on CsA. Acetylcholine
and sodiumnitroprusside were infused into the brachial artery at increas-
ing concentrations (1—40 rg/min), and forearm blood flow response was
measured by semicontinuous venous occlusion strain gauge plethysmog-
raphy. Forearm vascular resistance was calculated by dividing mean
arterial pressure by forearm blood flow. Twelve patients, aged 53 13
years (mean sEM) and 17 8 months after transplantation were
included, and studied both while on CsA treatment and 3 months after
conversion to azathioprine-based immunosuppressive therapy. Antihyper-
tensive drugs were withdrawn 3 days before the investigation. After
conversion intraarterial mean pressure fell from 114.1 4.5 mm Hg to
104.3 3.9 mm Hg (P < 0.01), and baseline forearm vascular resistance
decreased from 27.1 4.1 U during CsA therapy to 20.9 2.3 U during
azathioprine therapy (P < 0.01). Acetylcholinc-induced decreases in
forearm vascular resistance during CsA and azathioprine treatment were
not different, as were the sodiumnitroprusside-induced decreases in
forearm vascular resistance. Our study demonstrates that forearm vascular
resistance is increased in patients with CsA-induced hypertension. How-
ever, in contrast to reported results of in Vitro and animal studies, the
increased resistance seems to be accompanied by preserved endothelium-
dependent vasodilation.
Glomerular barrier function following conversion from cyclosporine A
to azathioprine in renal transplant recipients. R. Zietse, M.L. van
lerland-van Leeuwen, F.H.M Derkr, MA. van den Dorpel, M.A.D.H.
Schalekamp, and W. Weimar, Department of Internal Medicine I, University
Hospital Dijkzigt, Rotterdam, The Netherlands. The renal side-effects are a
major limitation to the use of cyclosporine A (CsA) in clinical transplan-
tation. We studied the reversibility of changes in renal hemodynamics and
glomerular barrier function in 17 patients with moderately impaired renal
function at least 1 year after kidney transplantation. All patients were
studied both during CsA treatment and 3 months after conversion to
azathioprine (AZA). During AZA both glomerular filtration rate and
effective renal plasma flow increased significantly (from 44.3 4.2 to 63.5
5.4 mI/mm and from 192 12.8 to 260 14.6 mI/mm respectively,
means SEM). Despite the marked changes in renal hemodynamics, no
significant changes were observed in the fractional clearances of un-
charged dextrans. When calculating the characteristics of the filtration
barrier, we observed a trend towards an increase in the ultrafiltration
coefficient (K.). This trend was abolished when an increase in net filtration
pressure (P) was assumed to result from reduced prerenal vasoconstric-
tion. We conclude that, despite marked improvement of renal perfusion
and glomerular filtration, conversion from CsA to AZA did not signifi-
cantly alter the permeability characteristics of the glomerular barrier in
renal transplant recipients with moderately reduced renal function. Im-
provement in renal function following conversion could result from an
increase in either I( or P. Since renal plasma flow was increased
significantly, the observed improvement in glomerular filtration rate is
likely to be, at least in part, due to an increase in glomerular capillary
plasma flow.
Injection of monoclonal anti-aminopeptidase A (APA) antibodies in-
duces redistribution of APA in proximal tubular cells. S. Mentzel,
H.B.P.M. Dijkman, J.P.H.F. van Son, R.A.P. Koene, and KJ.M. Assmann,
University Hospital Ntjmegen, Nijmegen, The Netherlands. Previously, we
have characterized 8 monoclonal antibodies (mAb) directed against
mouse APA, a hydrolase present on glomerular visceral epithelial cells
(GEC) and brush borders (BB) of proximal tubules. Injection in mice of
an anti-APA mAb, (such as ASD-4) that blocks enzyme activity induces an
acute albuminuria. One day after injection no enzyme activity is observed
by enzyme histochemistry. However, using a biotinylated anti-APA mAb
we noticed that APA was redistributed from the luminal to the basolateral
cell membranes of the proximal tubular cells, while the glomerular
presence was unchanged. Injection of mAbs that do not block enzyme
activity does not result in proteinuria. However, these mAbs also caused a
redistribution of APA to the basolateral membranes, which was confirmed
by enzyme histochemistiy. Injection of anti-APA mAb did not change the
localization of dipeptidyl peptidase IV (DPP IV), another hydrolase on
the BB. Administration of polyclonal anti-GBM Ab or monoclonal
anti-DPP IV Ab did not influence the localization of APA or its enzyme
activity. In a time-related study with ASD-4, it was found that the
redistribution of APA in the proximal tubules occurred between 4 and 24
hours after injection of the mAb and gradually returned to normal after 10
days. In conclusion: Injection of anti-APA mAb induces a redistribution of
APA from the BB to the basolateral side of the proximal tubular cells.
This shift is specific since it effects only APA and not other hydrolases of
the BB. Furthermore, it is not related to the induction of albuminuria or
blockade of the enzyme activity.
Tolrestat pretreatment prevents the impairment of afferent arteriolar
(AA) responsiveness to pressure in galcatose-fed rats. P.M. ter Wee, H.
Forster, T Hohman, and M. Epstein, Nephrology Section, VAMC and
University of Miami, Miami, Florida, USA. Previously, we have demon-
strated an abolished AA responsiveness to pressure in 4—6 week diabetic
rats. Disordered polyol metabolism has been implicated as a possible
contributing factor in the altered renal hemodynamics of diabetic rats. In
the present study we investigated the role of intracellular polyol accumu-
lation in altering AA responsiveness of galactose-fed rats. Such rats
constitute a model of increased polyol activity without hyperglycemia or
insulin deficiency. Pressure-induced AA vasoconstriction was examined in
hydronephrotic kidneys (HK) from control rats (CON), rats fed a 50%
galactose diet alone (GAL), or GAL supplemented with the aldose
reductase inhibitor Tolrestat (TOL; 25 mg/kg). Hydronephrosis was
induced to permit videomicroscopy of renal microvessels. Myogenic
responsiveness was assessed by stepwise increments in renal arterial
pressure (RAP; from 80 to 180 mm Hg). Vessel diameters were measured
by computer-assisted image processing. In an additional study, intracellu-
lar galactitol content of non-hydronephrotic kidneys was measured in
CON, GAL and TOL rats utilizing capillary gas liquid chromatography.
As anticipated, no cortical galactitol accumulation could be demonstrated
in CON kidneys. Galactitol levels in GAL rats averaged 1.54 0.12
nmol/mg wet weight, which was markedly reduced in TOL rats (0.31
0.02 nmol/mg wet tissue; P < 0.01). AA from CON-HK constricted
markedly to increases in renal arterial perfusion pressure (17 1% at 180
mm Hg; N = 35; P < 0.001 vs. 80 mm Hg). AA responsiveness to pressure
was abolished in HK of GAL rats (4 2% diameter decrement at 180
mm Hg; N = 29; NS). In contrast, AA responsiveness of HK from TOL
1222 Abstracts
rats did not differ from that of control rats (16.5 2% constriction at 180
mm Hg; N = 31;P < 0.001). The impairment of myogcnic responsiveness
by galactose feeding and its prevention by Tolrestat pretreatment, which
was associated with a reduced intracellular galactitol content, implicate
disordered polyol metabolism in the pathogenesis of deranged autoregu-
lation in experimental diabetes.
Functional effects of a 21-aminosteroid on renal ischemia/reperfusion
injury in a rat model. M. Verbeke, J. Van de Voorde, L. de Ridder, and N.
Lameire, Departments of Histology, Normal and Pathological Physiology and
Nephrology, University of Gent, Gent, Belgium. Lazaroids or 21-aminos-
teroids are a group of antioxidant drugs without steroid activity, contain-
ing iron binding subgroups. They are found to be incorporated into the
lipid bilayer of the plasma membrane, where they act as lipid anti-
peroxidants at the moment of rcperfusion following ischemia. Beneficial
actions of this group of drugs are described in many organs, especially in
the central nervous system. Information on renal effects is, however, very
scarce. In the present study a possible advantageous effect of the lazaroid
U-743989G is analyzed in a rat model of renal ischemia/reperfusion. Male
OFA rats (± 300 g) are subjected to 40 minutes clamping of the right renal
artery. Five minutes before releasing the clamp, a bolus of 3 mg/kg of the
drug, or the same volume of the vehicle in the control group, is given iv.
Two hours later, the same dose is administered i.p. The functioning of the
right and left kidneys is evaluated separately by standard clearance
techniques before clamping and at different times after reflow (3 hours, 1,
2, 7 days). As shown in the following table, the inulin (In) and PAH
clearances of the post-ischemic kidneys from vehicle (V) and lazaroid
(L)-treated rats are similar during the considered reflow period (X SEM,
= 5—10, in mI/mm):
Before clamp
Reflow period
3 hours 1 day
CvAFI 2.39 0.12
Cth 0.94 0.04
V: 0.3 0.12
L: 0.34 0.12
V: 0.18 0.07
L: 0.18 0.08
0.04 0.04
0
0.01 0.01
0
Before clamp
Reflow period
2 days 7 days
0.72 0.21
1.29 0.38
0.24 0.07
0.33 0.1
CPAH 2.39 0.12
C1,, 0.94 0.04
V: 0.2 0.2
L: 0.45 0.1
V: 0.04 0.04
L: 0.12 0.04
Moreover, the fractional sodium excretion and diuresis showed a similar
behavior in both groups. This means that the lazaroid treatment in our
experimental conditions, opposed to data obtained by others in non-renal
tissues, does not protect the kidney against functional damage.
Why did the use of inonoclonal and polyclonal anti-lymphocyte anti-
bodies in kidney transplantation fail to improve graft survival? E.P.M.
van Steenberge, PG. Mulder, J.N. !Jzermans, and W Weimar, Department of
Internal Medicine I, Department of Epidemiology and Biostatistics, and
Department of General Surgery, University Hospital Dijkzigt Rotterdam,
Rotterdam, The Netherlands. To investigate the effect of the use of
monoclonal and polyclonal anti-lymphocyte rejection prophylaxis on
rejection and short- and long-term graft function in first cadaveric kidney
transplantation, we compared the outcome of 150 kidney recipients
treated with HALO prophylaxis (a horse anti-lymphocyte preparation)
continued for 6 days, 21 kidney recipients treated with OKT3 prophylaxis
(a murine monoclonal antibody) continued for 14 days, 54 recipients
treated with a single shot RATG prophylaxis (a rabbit anti-thymocyte
immunoglobulin), and 70 recipients who received the maintenance immu-
nosuppressive therapy with cyclosporine A (CsA) and steroids from day 0.
The treatment groups were retrospectively analyzed in unifactorial and
multifactorial fashion. The CsA group had the highest incidence of
immediate graft function. Logistic regression analyses revealed that the
use of 0KT3 (P = 0.029), duration of cold ischemia time (P < 0.001),
duration of pretranspiant dialysis (P = 0.002) and increasing donor-
recipient age difference (P < 0.001) were significantly associated with
delayed graft function. The use of OKT3 was also significantly associated
with the occurrence of never functioning graft (P = 0.02) due to renal
artery or renal vein thrombosis. The use of HALG, OKT3 and RATG
prophylaxis significantly reduced acute rejection within three months and
1 year post-transplant (P = 0.003 and P = 0.001, respectively, Fisher's
Exact test), but the incidence of therapy-resistant first rejection was
comparable between the 4 groups (P = 0.7 Fisher's Exact test). The Cox
proportional hazards analysis showed that University of Wisconsin (UW)
preservation solution (relative risk 0.51 P = 0.044), each mismatch on the
HLA ABDR loci (relative risk 1.34 P < 0.001), and each year of recipient
age (relative risk 0.97 P < 0.001) were also explanatory variables for acute
rejection within 1 year post-transplant. The incidences of cytomegalovirus
infection and malignancies within 5 years post-transplant were comparable
between the groups. The use of rejection prophylaxis had no significant
effect on the patient and graft survival in the Kaplan-Meier analysis and
Cox proportional hazards analysis. We conclude that although anti-
lymphocyte rejection prophylaxis effectively reduced acute rejection, it did
not increase graft survival due to the incidence of never functioning grafts
while the therapy-resistant acute rejection episodes remained comparable.
Verocytotoxin-producing Escherichia coli infection in hemolytic uremic
syndrome in Western Europe. N. van de Kar, H. Roelofs, H. Muytjens, J.
Tolboom, and L. Monnens, Departments of Pediatrics and Medical Micro-
biology, University Hospital, Nijmegen, The Netherlands. From September
1989 until September 1993, stool specimens and sera from 113 children
with diarrhea-associated hemolytic uremic syndrome (HUS) from the
Netherlands, 2 university hospitals in Belgium, and 1 university hospital in
Germany, were examined for the presence of Verocytotoxmn-producing
Escherichia coli (VTEC) infection. Stool examination for VTEC and for
free fecal Verocytotoxin combined with serological evidence of Verocy-
totoxins and antibodies to the lipopolysaccharide of 0157 antigen, dem-
onstrated a VTEC infection in 88 (78%) patients with HUS and in 2 (3%)
of the 65 examined control children with acute gastroenteritis. The
serotype 0157 was the causative agent in 86% of these 88 patients with
VTEC-associated HUS. VTEC 0157 strains were isolated from the stool
of 19 patients with HUS and in 1 of the controls. Cytotoxicity of the
culture filtrates of all isolated strains could be neutralized by antibodies to
Verocytotoxin-2. The fecal samples tested by a procedure for Verocyto-
toxin detection in polymyxin B extracts of colony sweeps (VTIPECS) and
free fecal Verocytotoxin (FVT) assays were positive in 27% and 54%,
respectively in the HUS group as compared to 2% in the control group.
Sera of 71(65%) of 110 patients with HUS and 1 control serum contained
antibodies to 0157 antigen. Serological testing for antibodies to 0157
0-antigen yielded the highest number of positive results compared to the
other test methods. Stool and sera examination for VTEC in 95 family
contacts of 28 patients with HUS demonstrated an evidence for VTEC
infection in 33 (35%) family contacts. Serological antibodies to 0157
0-antigen were found in only 3 (4%) of 85 family contacts. We conclude
from this study that in this part of Western Europe VT2-producing
Escherichia coli, mainly those belonging to serogroup 0157, are the major
cause of HUS in childhood.
The renal histology of Wegener's granulomatosis: Correlation of clin-
ical parameters and renal biopsy findings. A meta-analysis of 330
patients. I.M. Bajema, E.G. Hagen, F.J. van der Woude, and J.A. Bniijn,
Departments of Pathology and Nephrology, University Hospital Leiden,
Leiden, The Netherlands. It was recently suggested that there are 2 forms
of proliferative glomerulonephritis, 1 in which necrosis is present and I in
which necrosis is absent. The necrotic proliferative form would be ANCA
associated and indicative of vasculitis. The non-necrotic proliferative form
would be the result of a different pathogenesis. To test this hypothesis we
recorded the data of 330 patients with Wegener's granulomatosis tWGI
who were described in the literature over the past fifteen years. Two
hundred fifty-four patients were reported with renal involvement, whereas
76 patients were described with limited WG. We compared the clinical
parameters of these 2 groups. Cases were only submitted to the non-renal
group if they were completely void of any of the clinical renal parameters
that were included in our protocol, such as elevated serum creatinine,
protcinuria, microscopic hematuria, and positive urine sediment. The
non-renal group had significantly lower ESR and WBC, less anemia, less
multi-organ involvement, and fewer joint symptoms than the renal group.
Of 142 patients with renal involvement kidney biopsy results were
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available. The most frequently found lesion was proliferative glomcrulo-
nephritis with crescents N = 86), in more than half of the cases
accompanied by necrosis (N = 47). We dividcd the group of patients with
crescentic glomerulonephritis according to the presence or absence of
necrosis. The non-necrotic crescentic group showed a male sex predomi-
nance (male:female = 26:13); furthermore, mesangial proliferation was
almost uniquely found in this group (N = II, whereas only 1 case with
mesangial proliferation was reported in the necrotic crescentic group).
However, in terms of clinical parameters the 2 groups were strictly
homogeneous. This indicates that the presence of necrosis in the kidney
biopsy specimen in WG is not associated with unfavorable clinical
parameters, as is commonly believed. In WG one may find proliferative
glomerulonephritis without signs of necrosis; this is not supportive of the
hypothesis that necrosis is pathognomic for vasculitis.
The role of angiotensin H (Ang II) and bradykinin (BK) in the
antiproteinuric mechanism of ACE-inhibition in established adriamycin
(ADM) nephrosis. F.H. Wapsira, P. de fang, and D. de Zeeuw, University
Hospital Groningen, Groningen, The Netherlands. Recently, we demon-
strated that ACE-inhibition effectively reduces protcinuria (UP) in the rat
model of established ADM nephrosis. This may be a direct result of
decreased Ang II activity, or alternatively an increase in another peptide
such as BK. To differentiate between these 2 mechanisms we performed 4
series of chronic infusion experiments. Each series was performed in 12
male Wistar rats starting 6 weeks after ADM injection (2 mg/kg) when a
stable UP was reached. In the first series, 2 mg/kg/24 hr lisinopril (ACEi)
reduced blood pressure (BP) from fl4 4 to 67 2mm Hg (—41 2%)
aswellasUPfrom335 66to57 lOmgI24hr(—83 3%).Subsequent
intraperitoneal infusion of Ang 11(250 ng/kg/min) for 2 weeks restored BP
nearly completely to 90 2% of the prelisinopril values, whereas UP
reached only 50 3% of prelisinopril values. Subsequent withdrawal of
Ang II restored the antiproteinuric effect of lisinopril, whereas subsequent
withdrawal of ACEi restored UP to pre-ACEi levels. Apparently, Ang II
seemed to be only partially responsible for the antiprotcinuric effect of
ACE-inhibition. In the second series, lisinopril reduced BP from 121 5
to 68 2mm Hg (—46--±3%) and UP from 355 90 to 101 10 mg/24
hr (—72 3%). Subsequent intraperitoneat infusion of the BK antagonist
HOE 140 (1 mg/kg/24 hr) for 2 weeks showed either no effect on BP (68
2 to 68 2 mm Hg) nor on UP (101 10 to 131 35 mg/24 hr). To
test whether or not HOE-140 was able to influence the BK activity at all
in this model, we combined an exogenous BK infusion (1.5 mgIkgI24 hr),
without ACEi, for I week with a subsequent infusion for 1 week of HOE
140 (1 mg/kg/24 hr). Thereby, BK did induce a fall in BP from 117 3 to
97 4mm Hg (—17 2%) without a reduction of UP (458 99 to 503
98 mg/24 hr). The BP lowering effect of BK was reversed completely by
HOE 140 infusion (97 4 to 113 4 mm Hg), while the UP remained
unchanged (503 98 to 523 102 mg/24 hi). This may indicate that
alterations in BK do not play a role in the antiproteinuric mechanism of
ACE-inhibition. In the last series, an Ang H antagonist induced a similar
BP reduction from 119 I to 67 2 mm Hg (—44 3%) and
antiproteinuric effect from 336 41 to 98 19 mg124 hr (—71 2%)
compared. to ACE inhibition. In conclusion, the antiproteinuric effect of
ACE inhibition appears to he Ang II and not BK mediated in this rat
model. The fact that the antiproteinuric effect can only be partially
restored by exogenous Ang II, in contrast to BP, may suggest that Ang II
cannot reach the "antiproteinuric compartment," whereas ACE inhibition
and Ang II antagonist can.
The antiproteinuric elfect of blood pressure lowering agents: A meta-
analysis of comparative trials. R. T. Gansevoort, W.J. Sluiter, M.H. Hem-
melder, D. de Zeeuw, and P.E. de Jong, Groningen Institute for Drug Studies
(GIDS), Divisions of Nephrology and Endocrinology, Department of Medi-
cine, State University Hospital, Groningen, The Netherlands. Whether ACE
inhibitors (ACEi's) differ from other antihypertensives in antiproteinuric
efficacy is still controversial. We therefore performed a meta-analysis of
articles published on this issue. Our secondary objective was to investigate
whether there is a difference between diabetic and non-diabetic patients in
antiproteinuric response to blood pressure lowering agents. To identi' all
articles, we performed a computer search using bibliographic databases.
Articles thus found were supplemented with references from recent
publications. To minimize publication bias, only trials in which a direct
comparison was made between an ACEi and another antihypertcnsive
were included. Studies performed both in diabetic and in non-diabetic
patients were eligible. Included were 41 studies (N), comprising 1124
patients (N), of which 558 had non-diabetic renal disease.
Others
ACEI (N = 34, All (N 40,
N=593) N=632)
Uprot %
MAP %
[43 to 371 17% [—19 tO —151
—12% [—13 to —In —11% [—12 to —11.]
Other antihypertensives divided by class
CCA BB Rest
(N = 23, (N = 8, (N = 9,
N=394) N=129) N=109)
Uprot % —18% [—20 to —16] —17% (—22 to —11] —14% [—18 to —1
MAP %—12% [—12 to —111 —10% [—11 to —9] —12% [—13 to —11]
Data are weighed mean with 95% confidence interval; Abbreviations
are: Upr,,t, proteinuria; MAP, mean arterial pressure.
The mean antiproteinuric effect obtained with ACEi's was significantly
greater than that of the other antihypertensive drugs, whereas the blood
pressure lowering effect was equal. A wide interstudy variation in antipro-
teinuric response to "non-ACEi" antihypertensives was observed. Multi-
ple variable regression analysis was performed to assess what factors may
explain this heterogeneity. The class appeared of no importance: calcium
channel antagonists (CCA), beta-blockers (BB), and a rest group (rest)
showed a similar response. Patient characteristics, such as initial renal
function and MAP, partly explained the response variation, but most of it
appeared dependent on the blood pressure reduction achieved. Further-
more, with CCA's, the type of agent is of importance, nifedipine having
the least effect. A significantly greater antiproteinurie effect of "non-
ACEi" antihypertensives was found in diabetic patients compared to
non-diabetics. However, this coincided with a greater blood pressure
reduction. Adjusted for differences in blood pressure control, diabetics
showed even a slightly lesser antiproteinuric response to "non-ACEi"
antihypertensive compared to non-diabetics. In conclusion, ACEi's confer
an antiproteinuric effect beyond that attributable to their blood pressure
lowering effect. Other antihypertensives in general have little proteinuria
lowering effect, which is dependent on baseline characteristics, the fall in
blood pressure, and the type of CCA. After adjustment for fall in blood
pressure, there are no differences in antiproteinuric effect between
diabetic and non-diabetic patients.
Endothelial dysfunction precedes the development of microalbumin-
uria in insulin-dependent diabetes mellitus (IDDM). C.D.A. Stehouwer,
H.R.A. Fischer, and A.J.M Donker, Departments of Internal Medicine, Free
University Hospital, Amsterdam, and Ifsselland Hospital, Capelle aan den
IJssel, The Netherlands. Background: In IDDM, microalbuminuria predicts
the development of widespread vascular disease. Patients with microalbu-
minuria show generalized dysfunction of the vascular endothelium, but it
is unknown whether endothelial dysfunction precedes the development of
microalbuminuria. Methods: To investigate this, we studied the relation-
ship between urinary albumin excretion (UAE) and plasma levels of von
Witlebrand factor antigen (vWF), a marker of endothelial dysfunction, in
a cohort of 17 IDDM patients. Measurements were obtained at 4 time
points (examinations 1—4): at baseline and after (median) 24, 40 and 64
months. Results: All patients had normal (<15 JLglmin) UAE at the first
3 examinations. At the 4th examination, 11 patients had normal UAE and
6 had microalbuminuria [median 25.7 sglmin (range 15.3—42.8)]. Com-
pared to patients with normal UAE, microalbuminuric patients had higher
plasma vWF levels at the 2nd [median 200% (range 168—206) vs. 131%
(69—186)1, the 3rd [208% (188—270) vs. 125% (82—190)], and the 4th
examination [231% (202—269) vs. 132% (88—208), P < 0.001], but not at
baseline [128% (98—161) vs. 122% (87—210)]. A sustained elevation of
vWF at examinations 1—3 [2 measurements above the upper limit of
normal (150%)] predicted microalbuminuria at the 4th examination with
100% sensitivity and 82% specificity. Patients with or without microalbu-
minuria did not differ with regard to age, diabetes duration, blood
pressure, glycosytated hemoglobin, cholesterol, smoking habits, or extent
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of retinopathy. Conclusion: Endothelial dysfunction, as estimated by
plasma vWF concentration, precedes and may predict the development of
microalbuminuria in IDDM.
Role of systemic and renal hemodynamics in the antiproteinuric effect
of acute ACE inhibition (ACEi). M.H. Hemmelder, D. de Zeeuw, R. T
Gansevoort, and P.E. de Jong, Groningen Institute for Drug Studies (GIDS),
University Hospital Groningen, The Netherlands. Previously, we demon-
strated that the time course of the antiproteinuric response to ACEi is
dissociated from that of the systemic and renal hemodynamic response.
Whereas the hemodynamic changes during acute ACEi coincided with a
small fall in proteinuria, proteinuria decreased further during chronic
ACEi without a further change in hemodynamics. Furthermore, the
antiproteinuric response could not be reversed by exogenous angiotensin
II infusion, in contrast to the ACEi-induced hemodynamic changes. Both
findings question the role of hemodynamic changes in the antiproteinuric
response of chronic ACEi. However, systemic or renal hemodynamic
changes may still play a role in the initial antiproteinuric response to
ACEi. We therefore compared the effects of a single intravenous dose of
10 ml glucose 5% (P), 10 mg enalaprilic acid (E), and a continuous
nitroprusside infusion (N), serving as an antihypertensive control drug
without renal hemodynamic effects, at 3 separate study days in 9 patients
with non-diabetic renal disease and proteinuria > 3 g/day. Data are
presented in table as the maximal change from baseline values during 5
hours after drug administration. Effects of E and N are compared to P.
Baseline Placebo %
5.8 1.1MAP, mm Hg 102 4
GFR, mI/mm 93 5 —1.3 2.3
ERPF, mI/mm 482 28 —5.9 2.0
FF 0.20 0.01 6.6 1.5
Proteinuria, g/hr 0.27 0.02 —13.6 6.0
Enalaprilat % Nitroprusside %
—10.4 18bMAP; mm Hg 15b
GFR, mI/mm —3.2 2.0 1.3 2.5
ERPF, mI/mm 12.6 5.1k' —4.5 2.4
FF —11.3 33b 6.0 1.4
Proteinuria g/hr —20.4 3.2a —24.6 5.2a
Data are mean SE; ap < 0.05; and bp < 0.01.
MAP fell similarly during E and N. Renal hemodynamics did not change
during N, while ERPF rose and FF fell significantly during E. Interest-
ingly, proteinuria fell similarly during both E and N. In 7 out of 9 patients
who had shown an antiproteinuric response to acute ACEi, exogenous
angiotensin II (Ang II) was infused from 2.5 hours after administration of
E onwards during a subsequent test day; Ang II infusion reversed the fall
in proteinuria to E, as well as the ACEi-induced changes in MAP and FF.
In conclusion, the acute antiproteinuric response of ACEi seems to be
mediated by systemic, but not renal, hemodynamic changes. The simulta-
neous recovery of the antiproteinuric and hemodynamic response of acute
ACEi by infusion of exogenous Ang TI corroborates this observation. In
this respect however, the role of renal hemodynamic changes may also be
questioned in the antiproteinuric response to acute ACEi.
High serum prorenin is a risk factor for microalbuminuria in patients
with insulin-dependent diabetes mellitus. A 10-year follow-up study.
F.H.M. Derkx, B. Ronn, R.J.A. de Bndn, ER. Mathiesen, H. Foght, T
Deckert, and M.A.D.H. Schalekamp, Department of Internal Medicine 1,
University Hospital Dijkzigt, Rotterdam, The Netherlands, and Steno Diabe-
tes Center, Copenhagen, Denmark. Aim: Prorenin (PR) is elevated in many
patients with insulin-dependent diabetes mellitus (IDDM) complicated by
microvascular disease. It is not known, however, whether high PR is a
marker of the presence and extent of microvascular involvement or
whether it is a risk factor for this complication. Patients and study design:
We measured renin (R) and PR in 209 TDDM patients who were enrolled
in a 10-year follow-up study at the Steno Diabetes Centre between
October 1982 and January 1983. Inclusion criteria were: age 18—50 years
duration of diabetes 10—30 years, diastolic blood pressure (BP) < 100 mm
Hg, and urinary albumin excretion (UAE) <30 mg/24 hr during the first
year of observation. UAE was measured every 4 months. Glycated Hb,
serum creatinine, and BP were measured annually. Serum for R and PR
was also collected annually; we obtained 82% of the planned samples.
Serum samples from patients on antihypertensive medication (started
when BP > 160/95 mm Hg), pregnant patients, and patients with
coexisting diseases were not included in the present analysis. Methods: We
developed a novel one-step sandwich immunoradiometric assay in which
PR is quantitatively converted, by the addition of a R inhibitor, into a form
that is recognized by a monoclonal antibody reacting with R but not with
native PR. Results: Of the 197 patients eligible for analysis, 29 developed
microalbuminuria (pAlb, UAE > 30 mg/24 hr). The occurrence of A1b
during follow-up strongly and directly correlated with the level of PR at
entry, but not with the level of R.
PR at entry, pU/ml
Risk for jAlb, %
<350 (N = 137)
11.7
350 (N = 60)
21.7
P < 0.001
PR at entry pJJ/ml <450 (N = 173) 450 (N = 24)
Risk for iAlb, % 12.1
P <
PR at entry pu/mI <550 (N = 186) 550 (N 11)
Risk for pAlb, % 12.4
P <
In patients with jrAlb, PR increased by 20% during the course of the study
but this increase did not correlate with the increase in UAE. PR was
unrelated to age, gender, or duration of diabetes. Conclusion: High PR is
an independent risk factor for Alb in IDDM. This finding is consistent
with other data suggesting a role for the renin-angiotensin system in the
pathogenesis of diabetic nephrbpathy.
Effect of suiphated glycosaminoglycans on proteinuria in patients with
overt (type!) nephropathy. F.J. van der Woude, J.T Tamsma, and H.H.P.J.
Lemkes, Departments of Nephrology and Endocrinology, University Hospital
Leiden, Leiden, The Netherlands. Decreased expression of heparan sul-
phate has been shown in the glomerular basement membrane of patients
with overt diabetic nephropathy. Low molecular weight heparin is a highly
sulphated glycosaminoglycan which has strong structural and functional
similarities to heparan sulphate. In experimental diabetes these glycosami-
noglycans could prevent the development of diabetic nephropathy. In a
first small study, we set out to assess if low molecular weight heparin
(LMWH) would be able to affect the albumin excretion rate (AER) in
diabetic patients with overt nephropathy. Six patients entered a random-
ized, double-blind, placebo-controlled crossover study with treatment
episodes of 1 month, separated by a 1 month washout. Patients received
prefilled syringes containing a clear solution with either placebo or
enoxaparin (40 mg/0.4 ml). They were educated to self-administer the
medication subcutaneously in an abdominal skinfold before the night.
Baseline AER levels before placebo and enoxaparin treatment were
similar. AER significantly decreased from 447 (181—1 102) to 295 (100—
873) .rg/min after 1 month treatment with low molecular weight heparin
(P < 0.05). This was not observed during placebo treatment. In the
comparison between placebo and LMWH treatment, the group difference
did not reach statistical significance after 1 month treatment (P = 0.16).
Hemodynamic variables including glomerular filtration rate and filtration
fraction did not change during enoxaparin treatment. In conclusion, we
observed a favorable effect of LMWH on AER in diabetic patients with
overt nephropathy. These data suggest that long-term treatment trials with
sulphated glycosaminoglycans in a larger group of patients may potentially
demonstrate a new therapeutic option for patients with overt diabetic
nephropathy.
